ClinicalTrials.gg
RecruitingNCT07774962DISCO-SHOCKUpdated Aug 19, 2026

Discordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock

An observational study in Septic Shock and Sepsis, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Istanbul University - Cerrahpasa · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

In septic shock, restoring large-vessel (macrocirculatory) perfusion-reflected by a normal capillary refill time (CRT)-does not always mean that oxygen use at the tissue level has recovered. This mismatch, sometimes called loss of hemodynamic coherence, may be detectable by comparing CRT with the oxygen extraction ratio (O₂ER), a marker of how much oxygen the tissues are extracting from the blood. Patients whose CRT has normalized but whose O₂ER remains abnormal-either too high (suggesting oxygen delivery that is insufficient for demand) or too low (suggesting microcirculatory shunting)-are considered to have a "discordant" perfusion phenotype.

This prospective, single-center, observational cohort study aims to determine how often this CRT-O₂ER discordance occurs at the 6th hour of resuscitation in adult patients with septic shock, and whether it is associated with 28-day mortality. Approximately 100 consecutive adult patients diagnosed with septic shock (with pre-existing central venous and arterial catheters) will be followed. Clinical and laboratory measurements-including CRT, O₂ER, lactate, mottling score, and organ dysfunction scores-will be recorded at hours 0, 6, 12, and 24, with the main phenotype grouping performed at hour 6. The study is purely observational: CRT is a painless, non-invasive bedside measurement, and O₂ER is calculated from blood gas samples already drawn as part of routine care, so no additional interventions or blood draws are performed for research purposes.

Read the detailed description

Background. In septic shock resuscitation, improvement of macrocirculatory targets such as blood pressure and capillary refill time (CRT) does not always reflect adequate oxygen utilization at the tissue level-a phenomenon described as loss of hemodynamic coherence. Although the ANDROMEDA-SHOCK trial highlighted CRT-targeted resuscitation, a subset of patients with a normalized CRT may still have impaired tissue oxygen balance. The oxygen extraction ratio (O₂ER) can deviate in two directions: a high O₂ER (>30%) suggests oxygen delivery that is insufficient for demand (e.g., low cardiac output, anemia), whereas a low O₂ER (\<20%, with high central venous oxygen saturation) may reflect microcirculatory shunting and cytopathic hypoxia.

Primary aim. To determine the prevalence of the "discordant" phenotype-defined as a normalized CRT with an abnormal O₂ER at hour 6 of resuscitation-and to evaluate its association with 28-day mortality.

Secondary aims. (1) To examine the association between CRT/O₂ER-defined perfusion phenotypes and 28-day mortality, ICU and hospital length of stay, duration of mechanical ventilation, vasopressor-free days, and need for renal replacement therapy; (2) to validate the proposed O₂ER >30% threshold using ROC curve analysis and identify the optimal cut-off for mortality in this cohort; (3) to assess whether the discordant phenotype is an independent predictor of mortality after adjustment for age, APACHE II score, lactate, and noradrenaline dose using multivariable analysis; (4) to examine the relationship of discordance with complementary perfusion markers (lactate clearance, mottling score, venoarterial CO₂ difference).

Design and setting. Prospective, single-center, observational cohort study in an intensive care unit. Consecutive adult patients diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline will be enrolled. Time zero (Hour 0) is defined as the time of vasopressor (noradrenaline) initiation.

Measurements. While patients continue standard care, serial clinical and laboratory measurements are recorded at hours 0, 6, 12, and 24, and organ function at hour 72. CRT is measured in a standardized manner on the ventral surface of the distal phalanx of the right index finger after 10 seconds of firm pressure. O₂ER is calculated as (SaO₂ - ScvO₂) / SaO₂. At hour 6, CRT and blood gas sampling are performed simultaneously (within 15 minutes). Inter-rater reliability of CRT is assessed in the first 20-30 patients by two independent, blinded observers (ICC for continuous values; Cohen's kappa for the ≤3 s normal/abnormal classification).

Phenotype grouping (Hour 6). Group 1 - Concordant normal (CRT ≤3 s + O₂ER 20-30%); Group 2a - Discordant, high O₂ER (CRT ≤3 s + O₂ER >30%); Group 2b - Discordant, low O₂ER (CRT ≤3 s + O₂ER \<20%); Group 3 - Concordant abnormal (CRT >3 s + abnormal O₂ER). The primary group of interest is the combined discordant phenotype (Group 2a + Group 2b).

Outcomes. Primary outcome: 28-day mortality (counted from Hour 0). Secondary outcomes: ICU and hospital length of stay, duration of mechanical ventilation, time to vasopressor weaning, vasopressor-free days, hour-72 organ function (SOFA-2, ongoing vasopressor/ventilation, lactate), and need for renal replacement therapy.

Sample size and statistics. A target of approximately 100 consecutive patients was chosen so that an expected discordance prevalence of \~30% can be estimated with a 95% confidence interval half-width of ±9%. Descriptive statistics, normality testing (Shapiro-Wilk), and appropriate parametric/non-parametric group comparisons will be used. The prevalence of the discordant phenotype will be reported with 95% CI. ROC analysis (with AUC) will evaluate the O₂ER threshold for mortality. Multivariable binary logistic regression (parsimonious model: phenotype, APACHE II, lactate; events-per-variable ≈12) will identify independent predictors of mortality, reported as odds ratios with 95% CI. Survival across phenotype groups will be estimated by Kaplan-Meier analysis and compared with the log-rank test. Statistical significance is set at p \< 0.05.

02

Conditions studied

  • Septic Shock
  • Sepsis

Keywords

  • Capillary Refill Time
  • Oxygen Extraction Ratio
  • Tissue Perfusion
  • ScvO2
  • Microcirculation
  • Hemodynamic Coherence
  • Lactate
  • Observational Cohort Study
03

In context

Shock, Septic

1,078 studies on the registry are indexed under Shock, Septic; 232 are open to participants now.

This study's planned enrollment of 100 is close to the median of 108 across 406 observational studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 699 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive adult patients (≥18 years) admitted to a single-center intensive care unit and diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline, who already have a central venous catheter and an arterial line in place as part of their clinical care. Patients are enrolled from all admission sources (emergency department, ward, operating room, or external referral) and followed prospectively while receiving standard treatment. Patients with active bleeding, ongoing ECMO, conditions that make capillary refill time measurement unreliable (e.g., Raynaud phenomenon or significant peripheral vascular disease), death within the first 6 hours, or inability to obtain hour-6 CRT or blood gas measurements are not included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline
  • Presence of both a central venous catheter and an arterial line

Exclusion criteria

Exclusion Criteria:

  • Active bleeding
  • Ongoing extracorporeal membrane oxygenation (ECMO)
  • Raynaud phenomenon or significant peripheral vascular disease that makes capillary refill time measurement unreliable (e.g., critical ischemia, amputation, digital ulcer/necrosis, or inability to measure on the right index finger)
  • Death within the first 6 hours
  • Inability to obtain hour-6 CRT or blood gas (phenotyping not possible)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • septic schoc cohort

    Consecutive adult patients (≥18 years) admitted to the intensive care unit and diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline, who have pre-existing central venous and arterial catheters. Patients are prospectively followed while receiving standard care, with serial measurements at hours 0, 6, 12, and 24 (time zero = vasopressor initiation). At hour 6, patients are classified into perfusion phenotypes based on capillary refill time (CRT) and oxygen extraction ratio (O₂ER): concordant normal, discordant with high O₂ER, discordant with low O₂ER, and concordant abnormal. The primary group of interest is the combined discordant phenotype (normalized CRT with abnormal O₂ER).

    Diagnostic Test: Capillary refill time (CRT) · Diagnostic Test: Oxygen extraction ratio (O₂ER) assessment

Interventions

  • Diagnostic testCapillary refill time (CRT)

    Non-invasive, standardized bedside measurement of capillary refill time on the right index finger.

  • Diagnostic testOxygen extraction ratio (O₂ER) assessment

    Oxygen extraction ratio calculated as (SaO₂ - ScvO₂)/SaO₂ from routinely obtained arterial and central venous blood gases.

06

What researchers measure

Primary outcomes

  1. Prevalence of the discordant CRT-O₂ER phenotype

    Proportion of patients classified as having a discordant perfusion phenotype (normalized CRT ≤3 s with an abnormal O₂ER, i.e., \>30% or \<20%; combined Group 2a + Group 2b) at hour 6, reported with 95% confidence interval.

    Time frame: At hour 6 of resuscitation (6 hours after vasopressor initiation)

  2. 28-day all-cause mortality

    All-cause mortality at 28 days, and its association with the hour-6 perfusion phenotype.

    Time frame: 28 days from Hour 0 (vasopressor initiation)

Secondary outcomes

  1. ICU length of stay

    Duration of intensive care unit stay in days.

    Time frame: Through study completion, up to 28 days

  2. Hospital length of stay

    Duration of hospital stay in days.

    Time frame: Through study completion, up to 28 days

  3. Duration of mechanical ventilation

    Total days on mechanical ventilation (0 if never ventilated).

    Time frame: Through study completion, up to 28 days

  4. Time to vasopressor weaning

    Time in hours to sustained vasopressor discontinuation (off ≥24 continuous hours), measured from Hour 0.

    Time frame: From Hour 0 up to 28 days

  5. Vasopressor-free days

    Number of days alive and free of vasopressor support within 28 days.

    Time frame: 28 days

  6. Organ dysfunction at hour 72

    SOFA-2 score at hour 72, together with ongoing vasopressor/mechanical ventilation status and lactate level.

    Time frame: Hour 72

  7. Need for renal replacement therapy (RRT)

    Proportion of patients requiring newly initiated RRT within 28 days (chronic dialysis patients excluded from the "new" category).

    Time frame: Within 28 days

Other outcomes

  1. Diagnostic performance of the O₂ER threshold for mortality

    Discriminative ability of O₂ER for 28-day mortality assessed by ROC analysis (area under the curve), with identification of the optimal cut-off and comparison to the literature threshold of 30%.

    Time frame: Hour 6 measurement; mortality at 28 days

  2. Inter-rater reliability of CRT measurement

    Agreement of hour-6 CRT between two independent, blinded observers; intraclass correlation coefficient (ICC) for continuous values and Cohen's kappa for the ≤3 s normal/abnormal classification.

    Time frame: Hour 6, first 20-30 patients

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jun 2027, 10 months later.

Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 10 months is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2026
First posted
Aug 19, 2026
StartEst.
Aug 17, 2026
Primary completionEst.
Jun 17, 2027
CompletionEst.
Jul 17, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07774962
Responsible party
tugba yesilyurt dogu (Intensive Care Medicine Fellow, Başakşehir Çam & Sakura City Hospital) — Principal investigator
First posted
Aug 19, 2026
Start date
Aug 17, 2026 (estimated)
Primary completion
Jun 17, 2027 (estimated)
Completion
Jul 17, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Tugba Yesilyurt Dogu, Intensive Medicine Care Fellow
Contact
tugbaayesilyurt@gmail.com
+9005535150847

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion